Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Yamamoto

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
Expert Opinion on Biological Therapy|June 11, 2024
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinomaNozomu Ogura, Shun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|October 21, 2022
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in JapanKentaro Harada, Shun Yamamoto, Ken Kato
Cancer Management and Research|May 17, 2023
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical DataYuntae Kim, Shun Yamamoto, Ken Kato
Future Oncology (London, England)|April 21, 2025
Tislelizumab for the treatment of advanced esophageal squamous cell carcinomaKazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety|April 27, 2024
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluationKazumasa Yamamoto, Shun Yamamoto, Ken Kato
Expert Review of Gastroenterology & Hepatology|July 12, 2021
Emerging data on nivolumab for esophageal squamous cell carcinomaToshiharu Hirose, Shun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|March 19, 2021
Nivolumab for the treatment of esophageal cancerHayato Mikuni, Shun Yamamoto, Ken Kato
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 10, 2023
[Comparison of Current Perspectives of Perioperative Treatments for Esophageal Cancer between Japan and the Western Countries-Toward International Collaborative Studies]Go Ikeda, Shun Yamamoto, Ken Kato
Future Oncology (London, England)|June 11, 2024
Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinomaToru Kadono, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety|July 15, 2021
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapyGo Ikeda, Shun Yamamoto, Ken Kato
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Expert Opinion on Biological Therapy|June 11, 2024
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinomaNozomu Ogura, Shun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|October 21, 2022
Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in JapanKentaro Harada, Shun Yamamoto, Ken Kato
Cancer Management and Research|May 17, 2023
Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical DataYuntae Kim, Shun Yamamoto, Ken Kato
Future Oncology (London, England)|April 21, 2025
Tislelizumab for the treatment of advanced esophageal squamous cell carcinomaKazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety|April 27, 2024
Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluationKazumasa Yamamoto, Shun Yamamoto, Ken Kato
Expert Review of Gastroenterology & Hepatology|July 12, 2021
Emerging data on nivolumab for esophageal squamous cell carcinomaToshiharu Hirose, Shun Yamamoto, Ken Kato
Expert Opinion on Biological Therapy|March 19, 2021
Nivolumab for the treatment of esophageal cancerHayato Mikuni, Shun Yamamoto, Ken Kato
Gan to Kagaku Ryoho. Cancer & Chemotherapy|February 10, 2023
[Comparison of Current Perspectives of Perioperative Treatments for Esophageal Cancer between Japan and the Western Countries-Toward International Collaborative Studies]Go Ikeda, Shun Yamamoto, Ken Kato
Future Oncology (London, England)|June 11, 2024
Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinomaToru Kadono, Shun Yamamoto, Ken Kato
Expert Opinion on Drug Safety|July 15, 2021
The safety of current treatment options for advanced esophageal cancer after first-line chemotherapyGo Ikeda, Shun Yamamoto, Ken Kato
Pageof 11